Trademark: 87953650
Word
BAUSCH HEALTH
Status
Registered
Status Code
700
Status Date
Tuesday, December 21, 2021
Serial Number
87953650
Registration Number
6598161
Registration Date
Tuesday, December 21, 2021
Mark Type
3000
Filing Date
Friday, June 8, 2018
Published for Opposition
Tuesday, January 29, 2019

Trademark Owner History
Bausch & Lomb Incorporated - Original Registrant

Classifications
5 Pharmaceutical preparations, namely, an oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;, namely, diazepam rectal gel; Pharmaceutical preparations for the treatment of cancer, neurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravis, depression, mood/anxiety conditions, solar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; antiviral pharmaceutical compounds; antiobesity agent in the nature of a pharmaceutical preparation; Dermotherapeutic preparation for use in the treatment of obesity; Pharmaceutical products, namely, lipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; Pharmaceutical preparations, namely, a topical cream for the treatment of pre-cancerous skin lesions; pharmaceutical preparations and substances for the prevention and treatment of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nausea, emesis; Medicines and medicinal preparations for human purposes, namely, to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical preparations and substances for the treatment of epilepsy, seizures and neurological and psychological diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations, namely, immunomodulators; anticholinesterase preparation for the prevention, treatment and alleviation of a neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness
The mark consists of the word "BAUSCH" in gray. The "H" in "BAUSCH" has an extended horizontal center forming a cross in which in the center of the cross is a blue square. The word "HEALTH" follows "BAUSCH" and appears in blue and lowercase, except the first letter "H". The color white represents background, outlining, shading, and/or transparent areas and is not part of the mark.
The color(s) gray and blue is/are claimed as a feature of the mark.
"HEALTH"

Trademark Events
Oct 11, 2023
Assignment Of Ownership Not Updated Automatically
Dec 28, 2022
Assignment Of Ownership Not Updated Automatically
Dec 21, 2022
Assignment Of Ownership Not Updated Automatically
Dec 14, 2022
Assignment Of Ownership Not Updated Automatically
Oct 10, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 10, 2022
Teas Change Of Correspondence Received
Oct 10, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 10, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 10, 2022
Teas Change Of Owner Address Received
Jun 23, 2022
Assignment Of Ownership Not Updated Automatically
May 25, 2022
Assignment Of Ownership Not Updated Automatically
Mar 9, 2022
Assignment Of Ownership Not Updated Automatically
Dec 21, 2021
Registered-Principal Register
Nov 19, 2021
Notice Of Acceptance Of Statement Of Use E-Mailed
Nov 18, 2021
Allowed Principal Register - Sou Accepted
Nov 10, 2021
Statement Of Use Processing Complete
Nov 7, 2021
Use Amendment Filed
Nov 7, 2021
Teas Statement Of Use Received
Oct 16, 2021
Teas Change Of Correspondence Received
Oct 16, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 16, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Sep 10, 2021
Notice Of Approval Of Extension Request E-Mailed
Sep 9, 2021
Sou Extension 5 Granted
Sep 5, 2021
Sou Extension 5 Filed
Sep 5, 2021
Sou Teas Extension Received
Mar 23, 2021
Notice Of Approval Of Extension Request E-Mailed
Mar 21, 2021
Sou Extension 4 Granted
Mar 21, 2021
Sou Extension 4 Filed
Mar 21, 2021
Sou Teas Extension Received
Nov 25, 2020
Assignment Of Ownership Not Updated Automatically
Sep 29, 2020
Notice Of Approval Of Extension Request E-Mailed
Sep 25, 2020
Sou Extension 3 Granted
Sep 25, 2020
Sou Extension 3 Filed
Sep 25, 2020
Sou Teas Extension Received
May 11, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
May 11, 2020
Teas Change Of Correspondence Received
May 11, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
May 11, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 11, 2020
Teas Change Of Owner Address Received
Mar 28, 2020
Notice Of Approval Of Extension Request E-Mailed
Mar 26, 2020
Sou Extension 2 Granted
Mar 26, 2020
Sou Extension 2 Filed
Mar 26, 2020
Sou Teas Extension Received
Oct 30, 2019
Notice Of Approval Of Extension Request E-Mailed
Oct 29, 2019
Sou Extension 1 Granted
Sep 26, 2019
Sou Extension 1 Filed
Oct 29, 2019
Case Assigned To Intent To Use Paralegal
Sep 30, 2019
Notice Of Revival - E-Mailed
Sep 27, 2019
Sou Extension Received With Teas Petition
Sep 27, 2019
Petition To Revive-Granted
Sep 27, 2019
Teas Petition To Revive Received
Mar 26, 2019
Noa E-Mailed - Sou Required From Applicant
Jan 29, 2019
Official Gazette Publication Confirmation E-Mailed
Jan 29, 2019
Published For Opposition
Jan 9, 2019
Notification Of Notice Of Publication E-Mailed
Dec 22, 2018
Approved For Pub - Principal Register
Dec 21, 2018
Teas/Email Correspondence Entered
Dec 20, 2018
Correspondence Received In Law Office
Dec 20, 2018
Teas Response To Office Action Received
Dec 19, 2018
Notification Of Non-Final Action E-Mailed
Dec 19, 2018
Non-Final Action E-Mailed
Dec 19, 2018
Non-Final Action Written
Dec 11, 2018
Previous Allowance Count Withdrawn
Nov 20, 2018
Withdrawn From Pub - Og Review Query
Nov 2, 2018
Assigned To Lie
Oct 22, 2018
Approved For Pub - Principal Register
Oct 22, 2018
Teas/Email Correspondence Entered
Oct 22, 2018
Correspondence Received In Law Office
Oct 22, 2018
Teas Response To Office Action Received
Oct 4, 2018
Notification Of Non-Final Action E-Mailed
Oct 4, 2018
Non-Final Action E-Mailed
Oct 4, 2018
Non-Final Action Written
Sep 24, 2018
Teas/Email Correspondence Entered
Sep 22, 2018
Correspondence Received In Law Office
Sep 22, 2018
Teas Response To Office Action Received
Aug 15, 2018
Notification Of Non-Final Action E-Mailed
Aug 15, 2018
Non-Final Action E-Mailed
Aug 15, 2018
Non-Final Action Written
Aug 15, 2018
Assigned To Examiner
Jun 15, 2018
Notice Of Design Search Code E-Mailed
Jun 14, 2018
New Application Office Supplied Data Entered
Jun 12, 2018
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24